StockNasdaqGSVRTX
Vertex Pharmaceuticals
$547.09
+9.99 (+1.86%)today
Valuation & earnings
- P/E ratio
- 35.21
- Forward P/E
- 27.47
- EPS (ttm)
- $15.54
- Forward EPS
- $19.92
- Price/book
- 6.63
- PEG ratio
- 2.17
- Dividend yield
- 0%
- Payout ratio
- 0%
Financials (ttm)
- Revenue (ttm)
- 13B
- Revenue growth
- 11.8%
- Profit margin
- 30.7%
- Return on equity
- 20.8%
- Total cash
- 6.3B
- Total debt
- 6.5B
Earnings (EPS)
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 4.31 | 4.47 | +3.81% |
| Dec 31, 2025 | 4.58 | 4.65 | +1.43% |
| Jun 30, 2026 | 4.75 | 4.73 | -0.32% |
| Sep 30, 2026 | 4.78 | 4.76 | -0.5% |
Next earnings date: Nov 2, 2026
Analyst view
Consensus ratingBuy32 analysts
Strong buy 6Buy 20Hold 5Sell 1
12-month price targetsImplied upside: +8.27%
350
592.36
725
LowCurrent priceHigh
Related products
How visible is Vertex Pharmaceuticals in AI search?
We ask AI search engines about Vertex Pharmaceuticals and its market — live — and measure whether and how prominently the brand appears in their answers.
No AI visibility check has been run for Vertex Pharmaceuticals yet.
Run a live check to see how AI search engines talk about this brand right now.
Is your brand this visible in AI search?
Aurora tracks your brand across 7 AI search engines — visibility, share of voice and the sources that shape AI answers.